Oncotelic Therapeutics (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003. The committee found no dose-limiting toxicities and recommended advancement to the next planned dose level, marking a significant milestone for the company's lead candidate.
Sapu003 is an intravenous formulation of everolimus based on the Deciparticle nanomedicine platform. The company also announced plans to expand the study into Europe by adding clinical sites, which is expected to broaden patient access and support enrollment. This strategic move could accelerate the development timeline and provide access to a larger patient population for the trial.
The clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle platform and the Sapu003 formulation. According to the company, the publication supports the platform's scalable manufacturing capabilities, stability, and preclinical antitumor activity, reinforcing the ongoing clinical development program. The research provides a scientific basis for the platform's potential in oncology.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products addressing high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, Oncotelic licenses and co-develops drug candidates through joint ventures, including a 45% ownership stake in GMP Bio. The company also develops PDAOAI, a proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing.
The positive safety review is a critical step for Sapu003, as it demonstrates the formulation's tolerability at the initial dose level. For investors, this de-risks the program and supports progression to higher dose levels, which could yield efficacy data. The planned European expansion may also enhance the trial's enrollment and diversity, potentially leading to more robust results. If successful, Sapu003 could offer a new treatment option for cancer patients who require everolimus therapy but face limitations with oral administration.
For more information, visit the company's website at www.oncotelic.com. The full press release is available at https://ibn.fm/sBbID.
